The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma

Ezgi Ozyerli-Goknar, Ilknur Sur-Erdem, Fidan Seker, Ahmet Cingöz, Alisan Kayabolen, Zeynep Kahya-Yesil, Fırat Uyulur, Melike Gezen, Nazife Tolay, Batu Erman, Mehmet Gönen, James Dunford, Udo Oppermann, Tugba Bagci-Onder

Research output: Contribution to journalArticle

Abstract

Glioblastoma Multiforme (GBM) is the most common and aggressive primary brain tumor. Despite recent developments in surgery, chemo- and radio-therapy, a currently poor prognosis of GBM patients highlights an urgent need for novel treatment strategies. TRAIL (TNF Related Apoptosis Inducing Ligand) is a potent anti-cancer agent that can induce apoptosis selectively in cancer cells. GBM cells frequently develop resistance to TRAIL which renders clinical application of TRAIL therapeutics inefficient. In this study, we undertook a chemical screening approach using a library of epigenetic modifier drugs to identify compounds that could augment TRAIL response. We identified the fungal metabolite chaetocin, an inhibitor of histone methyl transferase SUV39H1, as a novel TRAIL sensitizer. Combining low subtoxic doses of chaetocin and TRAIL resulted in very potent and rapid apoptosis of GBM cells. Chaetocin also effectively sensitized GBM cells to further pro-apoptotic agents, such as FasL and BH3 mimetics. Chaetocin mediated apoptosis sensitization was achieved through ROS generation and consequent DNA damage induction that involved P53 activity. Chaetocin induced transcriptomic changes showed induction of antioxidant defense mechanisms and DNA damage response pathways. Heme Oxygenase 1 (HMOX1) was among the top upregulated genes, whose induction was ROS-dependent and HMOX1 depletion enhanced chaetocin mediated TRAIL sensitization. Finally, chaetocin and TRAIL combination treatment revealed efficacy in vivo. Taken together, our results provide a novel role for chaetocin as an apoptosis priming agent and its combination with pro-apoptotic therapies might offer new therapeutic approaches for GBMs.

Original languageEnglish (US)
Article number894
JournalCell Death and Disease
Volume10
Issue number12
DOIs
StatePublished - Dec 1 2019

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
Glioblastoma
Apoptosis
Heme Oxygenase-1
Therapeutics
DNA Damage
chaetocin
Transferases
Radio
Epigenomics
Brain Neoplasms
Histones
Libraries
Neoplasms
Antioxidants

ASJC Scopus subject areas

  • Immunology
  • Cellular and Molecular Neuroscience
  • Cell Biology
  • Cancer Research

Cite this

Ozyerli-Goknar, E., Sur-Erdem, I., Seker, F., Cingöz, A., Kayabolen, A., Kahya-Yesil, Z., ... Bagci-Onder, T. (2019). The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma. Cell Death and Disease, 10(12), [894]. https://doi.org/10.1038/s41419-019-2107-y

The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma. / Ozyerli-Goknar, Ezgi; Sur-Erdem, Ilknur; Seker, Fidan; Cingöz, Ahmet; Kayabolen, Alisan; Kahya-Yesil, Zeynep; Uyulur, Fırat; Gezen, Melike; Tolay, Nazife; Erman, Batu; Gönen, Mehmet; Dunford, James; Oppermann, Udo; Bagci-Onder, Tugba.

In: Cell Death and Disease, Vol. 10, No. 12, 894, 01.12.2019.

Research output: Contribution to journalArticle

Ozyerli-Goknar, E, Sur-Erdem, I, Seker, F, Cingöz, A, Kayabolen, A, Kahya-Yesil, Z, Uyulur, F, Gezen, M, Tolay, N, Erman, B, Gönen, M, Dunford, J, Oppermann, U & Bagci-Onder, T 2019, 'The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma', Cell Death and Disease, vol. 10, no. 12, 894. https://doi.org/10.1038/s41419-019-2107-y
Ozyerli-Goknar E, Sur-Erdem I, Seker F, Cingöz A, Kayabolen A, Kahya-Yesil Z et al. The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma. Cell Death and Disease. 2019 Dec 1;10(12). 894. https://doi.org/10.1038/s41419-019-2107-y
Ozyerli-Goknar, Ezgi ; Sur-Erdem, Ilknur ; Seker, Fidan ; Cingöz, Ahmet ; Kayabolen, Alisan ; Kahya-Yesil, Zeynep ; Uyulur, Fırat ; Gezen, Melike ; Tolay, Nazife ; Erman, Batu ; Gönen, Mehmet ; Dunford, James ; Oppermann, Udo ; Bagci-Onder, Tugba. / The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma. In: Cell Death and Disease. 2019 ; Vol. 10, No. 12.
@article{dd0b9ad9aeb446e09bd49f050666cf23,
title = "The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma",
abstract = "Glioblastoma Multiforme (GBM) is the most common and aggressive primary brain tumor. Despite recent developments in surgery, chemo- and radio-therapy, a currently poor prognosis of GBM patients highlights an urgent need for novel treatment strategies. TRAIL (TNF Related Apoptosis Inducing Ligand) is a potent anti-cancer agent that can induce apoptosis selectively in cancer cells. GBM cells frequently develop resistance to TRAIL which renders clinical application of TRAIL therapeutics inefficient. In this study, we undertook a chemical screening approach using a library of epigenetic modifier drugs to identify compounds that could augment TRAIL response. We identified the fungal metabolite chaetocin, an inhibitor of histone methyl transferase SUV39H1, as a novel TRAIL sensitizer. Combining low subtoxic doses of chaetocin and TRAIL resulted in very potent and rapid apoptosis of GBM cells. Chaetocin also effectively sensitized GBM cells to further pro-apoptotic agents, such as FasL and BH3 mimetics. Chaetocin mediated apoptosis sensitization was achieved through ROS generation and consequent DNA damage induction that involved P53 activity. Chaetocin induced transcriptomic changes showed induction of antioxidant defense mechanisms and DNA damage response pathways. Heme Oxygenase 1 (HMOX1) was among the top upregulated genes, whose induction was ROS-dependent and HMOX1 depletion enhanced chaetocin mediated TRAIL sensitization. Finally, chaetocin and TRAIL combination treatment revealed efficacy in vivo. Taken together, our results provide a novel role for chaetocin as an apoptosis priming agent and its combination with pro-apoptotic therapies might offer new therapeutic approaches for GBMs.",
author = "Ezgi Ozyerli-Goknar and Ilknur Sur-Erdem and Fidan Seker and Ahmet Cing{\"o}z and Alisan Kayabolen and Zeynep Kahya-Yesil and Fırat Uyulur and Melike Gezen and Nazife Tolay and Batu Erman and Mehmet G{\"o}nen and James Dunford and Udo Oppermann and Tugba Bagci-Onder",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41419-019-2107-y",
language = "English (US)",
volume = "10",
journal = "Cell Death and Disease",
issn = "2041-4889",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma

AU - Ozyerli-Goknar, Ezgi

AU - Sur-Erdem, Ilknur

AU - Seker, Fidan

AU - Cingöz, Ahmet

AU - Kayabolen, Alisan

AU - Kahya-Yesil, Zeynep

AU - Uyulur, Fırat

AU - Gezen, Melike

AU - Tolay, Nazife

AU - Erman, Batu

AU - Gönen, Mehmet

AU - Dunford, James

AU - Oppermann, Udo

AU - Bagci-Onder, Tugba

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Glioblastoma Multiforme (GBM) is the most common and aggressive primary brain tumor. Despite recent developments in surgery, chemo- and radio-therapy, a currently poor prognosis of GBM patients highlights an urgent need for novel treatment strategies. TRAIL (TNF Related Apoptosis Inducing Ligand) is a potent anti-cancer agent that can induce apoptosis selectively in cancer cells. GBM cells frequently develop resistance to TRAIL which renders clinical application of TRAIL therapeutics inefficient. In this study, we undertook a chemical screening approach using a library of epigenetic modifier drugs to identify compounds that could augment TRAIL response. We identified the fungal metabolite chaetocin, an inhibitor of histone methyl transferase SUV39H1, as a novel TRAIL sensitizer. Combining low subtoxic doses of chaetocin and TRAIL resulted in very potent and rapid apoptosis of GBM cells. Chaetocin also effectively sensitized GBM cells to further pro-apoptotic agents, such as FasL and BH3 mimetics. Chaetocin mediated apoptosis sensitization was achieved through ROS generation and consequent DNA damage induction that involved P53 activity. Chaetocin induced transcriptomic changes showed induction of antioxidant defense mechanisms and DNA damage response pathways. Heme Oxygenase 1 (HMOX1) was among the top upregulated genes, whose induction was ROS-dependent and HMOX1 depletion enhanced chaetocin mediated TRAIL sensitization. Finally, chaetocin and TRAIL combination treatment revealed efficacy in vivo. Taken together, our results provide a novel role for chaetocin as an apoptosis priming agent and its combination with pro-apoptotic therapies might offer new therapeutic approaches for GBMs.

AB - Glioblastoma Multiforme (GBM) is the most common and aggressive primary brain tumor. Despite recent developments in surgery, chemo- and radio-therapy, a currently poor prognosis of GBM patients highlights an urgent need for novel treatment strategies. TRAIL (TNF Related Apoptosis Inducing Ligand) is a potent anti-cancer agent that can induce apoptosis selectively in cancer cells. GBM cells frequently develop resistance to TRAIL which renders clinical application of TRAIL therapeutics inefficient. In this study, we undertook a chemical screening approach using a library of epigenetic modifier drugs to identify compounds that could augment TRAIL response. We identified the fungal metabolite chaetocin, an inhibitor of histone methyl transferase SUV39H1, as a novel TRAIL sensitizer. Combining low subtoxic doses of chaetocin and TRAIL resulted in very potent and rapid apoptosis of GBM cells. Chaetocin also effectively sensitized GBM cells to further pro-apoptotic agents, such as FasL and BH3 mimetics. Chaetocin mediated apoptosis sensitization was achieved through ROS generation and consequent DNA damage induction that involved P53 activity. Chaetocin induced transcriptomic changes showed induction of antioxidant defense mechanisms and DNA damage response pathways. Heme Oxygenase 1 (HMOX1) was among the top upregulated genes, whose induction was ROS-dependent and HMOX1 depletion enhanced chaetocin mediated TRAIL sensitization. Finally, chaetocin and TRAIL combination treatment revealed efficacy in vivo. Taken together, our results provide a novel role for chaetocin as an apoptosis priming agent and its combination with pro-apoptotic therapies might offer new therapeutic approaches for GBMs.

UR - http://www.scopus.com/inward/record.url?scp=85075624958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075624958&partnerID=8YFLogxK

U2 - 10.1038/s41419-019-2107-y

DO - 10.1038/s41419-019-2107-y

M3 - Article

C2 - 31772153

AN - SCOPUS:85075624958

VL - 10

JO - Cell Death and Disease

JF - Cell Death and Disease

SN - 2041-4889

IS - 12

M1 - 894

ER -